Increasing prevalence of Cancer is expected to propel growth of Cancer Diagnostics
![]() |
| Cancer Diagnostics |
Current Cancer Diagnostics and
therapy methods have severe limitations. With increasing knowledge and
technological advancement in cancer biology, material science, and especially
nanomedicine, novel nano-platforms providing simultaneous diagnostic and
therapeutic functions for cancer, known as theranostic agents or simply
theranostics, have emerged over the last decade. These innovative nanodevices
may target several cancer markers and kill cancer cells in synergistic ways,
addressing cancer heterogeneity and adaptive resistance. Cancer treatments
using theranostics can also be directed by diagnostic imaging data, resulting
in improved cancer therapy.
Ideal theranostics should be
compact in size and surface chemistry for optimal cellular absorption,
ultrasensitive imaging of many tumor-specific markers, ideal cancer targeting
capabilities, and, in particular, high loading and controlled release of
anticancer medicines. Other Cancer
Diagnostics, in addition to chemotherapy, are necessary in most
designs. Theranostics' multifunctional requirements are dependent on material
science and engineering developments, notably the creation of nanocomposites.
Inadequate reimbursement rules
are predicted to stymie market expansion. In recent years, there have been
several developments in radiology in terms of imaging equipment. However, most
medical insurance companies do not cover procedures that use computer-aided
detection (CAD). As a consequence, individuals choose traditional diagnostic
methods such as biopsies, pathology tests, or conventional imaging methods such
as mammography and MRI treatments. Furthermore, the high cost of cancer
detection software is projected to stifle market expansion. Computer-aided
Detection (CAD) software comes with a one-year licence, which hospitals must
renew each year. Furthermore, some insurance companies are opting out of CAD
procedure reimbursement because it is deemed excessive and not preferred by
senior radiologists.
There are various types of
nanocomposite theranostics that can diagnose cancer using photoluminescence,
SERS, MRI, ultrasonography, photoacoustics, or CT imaging (monomodal or
multimodal imaging) while also providing cancer therapy through drug and/or
gene delivery, photothermal therapy, photodynamic therapy, magnetic
hyperthermia, or combined therapy. Because the combinations of Cancer
Diagnostics and therapy for theranostics are many, it is difficult to discuss
them all here. Only a few common theranostics are discussed.
Cancer Diagnostics and treatment
advancements have resulted in a large improvement in survival rates,
particularly in paediatric tumours, resulting in a paradigm change in attention
toward long-term survivability and quality-of-life concerns. While cardiac,
pulmonary, renal, and hepatic functions are often evaluated before, during, and
after therapy, the reproductive system is not. As more girls and women survive
cancer, it is critical to predict the impact of cancer and its treatment on the
ovary and provide choices to safeguard this population's future reproductive
and sexual function.

Comments
Post a Comment